Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease.

World J Gastrointest Oncol · 2021 · PMC8371513 · PMID 34457186

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significanceP = 0.054so close (0.05 < p ≤ 0.1)

In another study, in which the overall rate of colitis was 2.3% across all ICI, the RR of colitis with anti-CTLA-4 use vs anti-PD-1/anti-PD-L1 use was higher, although it did not reach statistical significance ( P = 0.054)[ 30 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.